JP2024543385A5 - - Google Patents
Info
- Publication number
- JP2024543385A5 JP2024543385A5 JP2024527394A JP2024527394A JP2024543385A5 JP 2024543385 A5 JP2024543385 A5 JP 2024543385A5 JP 2024527394 A JP2024527394 A JP 2024527394A JP 2024527394 A JP2024527394 A JP 2024527394A JP 2024543385 A5 JP2024543385 A5 JP 2024543385A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- domain
- cdrs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163277966P | 2021-11-10 | 2021-11-10 | |
| US63/277,966 | 2021-11-10 | ||
| PCT/US2022/079668 WO2023086906A2 (en) | 2021-11-10 | 2022-11-10 | Sirp gamma antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024543385A JP2024543385A (ja) | 2024-11-21 |
| JP2024543385A5 true JP2024543385A5 (https=) | 2025-11-19 |
Family
ID=84488592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527394A Pending JP2024543385A (ja) | 2021-11-10 | 2022-11-10 | Ｓｉｒｐガンマ抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240400677A1 (https=) |
| EP (1) | EP4429768A2 (https=) |
| JP (1) | JP2024543385A (https=) |
| KR (1) | KR20240099454A (https=) |
| CN (1) | CN118591556A (https=) |
| AU (1) | AU2022386652A1 (https=) |
| CA (1) | CA3237787A1 (https=) |
| IL (1) | IL312776A (https=) |
| MX (1) | MX2024005740A (https=) |
| TW (1) | TW202334224A (https=) |
| WO (1) | WO2023086906A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023525298A (ja) | 2020-05-08 | 2023-06-15 | エレクトラ・セラピューティクス・インコーポレイテッド | Ｓｉｒｐアルファおよびｓｉｒｐベータ１抗体、ならびにそれらの使用 |
| WO2025226685A1 (en) * | 2024-04-22 | 2025-10-30 | Electra Therapeutics, Inc. | Sirp alpha, beta, gamma antibodies for treatment of epstein–barr virus infections |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018118887A1 (en) * | 2016-12-22 | 2018-06-28 | Wake Forest University Health Sciences | Sirp-gamma targeted agents for use in the treatment of cancer |
| JP7179743B2 (ja) * | 2017-02-17 | 2022-11-29 | オーエスイー・イミュノセラピューティクス | 抗ＳＩＲＰｇ抗体の新規の使用 |
| JP7763666B2 (ja) * | 2019-06-24 | 2025-11-04 | アムジェン インコーポレイテッド | 癌治療のためのＳＩＲＰγの阻害 |
-
2022
- 2022-11-10 WO PCT/US2022/079668 patent/WO2023086906A2/en not_active Ceased
- 2022-11-10 CA CA3237787A patent/CA3237787A1/en active Pending
- 2022-11-10 CN CN202280087148.6A patent/CN118591556A/zh active Pending
- 2022-11-10 JP JP2024527394A patent/JP2024543385A/ja active Pending
- 2022-11-10 IL IL312776A patent/IL312776A/en unknown
- 2022-11-10 MX MX2024005740A patent/MX2024005740A/es unknown
- 2022-11-10 EP EP22822810.2A patent/EP4429768A2/en active Pending
- 2022-11-10 TW TW111142996A patent/TW202334224A/zh unknown
- 2022-11-10 KR KR1020247019182A patent/KR20240099454A/ko active Pending
- 2022-11-10 AU AU2022386652A patent/AU2022386652A1/en active Pending
-
2024
- 2024-05-09 US US18/660,086 patent/US20240400677A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7434250B2 (ja) | Ｃｄ１９に対するヒト化抗原結合ドメイン及び使用方法 | |
| US11505613B2 (en) | BCMA binding molecules and methods of use thereof | |
| KR101695329B1 (ko) | 소아 급성 림프구성 백혈병의 치료방법 | |
| KR101197542B1 (ko) | 항-ｃｄ20 항체 및 이용 방법 | |
| CN113454119B (zh) | 抗btla抗体 | |
| RU2664462C9 (ru) | Комбинированная терапия с помощью антитела к CD19 и аналога пурина | |
| KR20080047540A (ko) | Ｃｄ20 특이적 결합 분자의 단회 투여 용도 | |
| CA3177398A1 (en) | Chimeric receptors and methods of use thereof | |
| RU2017134652A (ru) | Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) k cd19 | |
| CA2667808A1 (en) | Methods of treating neoplastic, autoimmune and inflammatory diseases | |
| CN112739715A (zh) | 抗cd38抗体的皮下给药 | |
| JP2023543152A5 (https=) | ||
| JP2008540447A5 (https=) | ||
| JP2024543385A5 (https=) | ||
| GB2613464A (en) | Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof | |
| WO2019246546A1 (en) | Chimeric antigen receptors targeting cd37 and cd19 | |
| JP2019530651A (ja) | マクロファージ活性化剤と組み合わせた抗ｃｓｆ−１ｒ抗体の間欠投与 | |
| JP2016507521A5 (https=) | ||
| Klingbeil et al. | Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use | |
| JP2020500161A5 (https=) | ||
| JP2023543835A5 (https=) | ||
| JP7156793B2 (ja) | 診断マーカーとしてのｂ細胞枯渇 | |
| CA3209172A1 (en) | Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection | |
| Meijer et al. | Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody | |
| Busca | The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation |